Skip to main content
Tom van Meerten
dr.

I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.

Je eigen bloedcellen als medicijn tegen een auto-immuunziekte of bloedkanker

Media contributions

Je eigen bloedcellen als medicijn tegen een auto-immuunziekte of bloedkanker

Media contributions

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

Media contributions

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

Media contributions

Prof. Tom van Meerten (UMCG) over beta-hydroxybutyraat en CAR T-cel fitness